SRTAW — Strata Critical Medical, Inc.

Summary of Strata Critical Medical, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $66.8 million, a 35.3% increase year-over-year, driven by logistics growth.
• Full-Year 2025 Revenue: $197.1 million, exceeding guidance.
• Adjusted EBITDA: $7.0 million in Q4 2025, up from $1.1 million in Q4 2024; full-year adjusted EBITDA was $14.1 million.
• Gross Profit: Increased 90% to $14.4 million in Q4, with a gross margin of 21.6%.
• Operating Cash Flow: Negative $8.3 million in Q4, impacted by nonrecurring items and working capital delays.
• Cash Position: Approximately $61.0 million in cash and short-term investments, with no debt.

2. Strategic Updates and Business Highlights

• Organic Growth: Achieved 35% organic growth in Q4, leading to an increase in full-year guidance for 2026.
• Acquisition Strategy: Continued focus on acquiring smaller businesses to enhance growth and geographic reach; multiple opportunities under exclusivity.
• Regulatory Environment: Positive regulatory changes expected to benefit the company, particularly regarding DCD (donation after circulatory death) organ recovery.
• Operational Developments: Expanded role for Dr. Scott Silvestri as Chief Medical Officer to enhance clinical capabilities.
• Aircraft Fleet: Ended the year with approximately 30 aircraft; one aircraft was parted out due to corrosion, resulting in a book loss of $1.7 million.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Raised to $260–$275 million from $255–$270 million.
• Adjusted EBITDA Guidance: Increased to $29–$33 million from $28–$32 million.
• Free Cash Flow Guidance: Reiterated at $15–$22 million.
• Q1 2026 Expectations: Anticipate a modest sequential revenue decline due to typical seasonal fluctuations and weather impacts, but expect improvement in Q2 and the latter half of the year.

4. Bad News, Challenges, or Points of Concern

• Operating Cash Flow: Negative cash flow in Q4 due to nonrecurring costs and working capital issues, which may affect liquidity in the short term.
• Weather Impact: Severe winter weather in the Northeast caused operational disruptions, potentially affecting Q1 performance.
• Regulatory Scrutiny: Ongoing regulatory scrutiny in the transplant sector could pose challenges, although the company is positioned well to adapt.

5. Notable Q&A Insights

• Regulatory Policy: Continuous distribution policy for organ allocation is progressing, but timelines for hearts and livers remain uncertain due to prioritization of other issues.
• Customer Integration: Approximately 40% of logistics growth in Q4 came from existing clinical customers, indicating successful cross-selling of services.
• Acquisition Pipeline: The company is focused on acquiring businesses that enhance its core competencies, with plans to announce new acquisitions as they close.
• Radiopharmaceuticals: Currently piloting services in this area, but no immediate plans for acquisitions; focus remains on core business growth.
• Fuel Price Impact: Fuel price increases will be passed through to customers, mitigating direct cost impacts on the company.

Overall, Strata Critical Medical, Inc. reported a strong quarter with significant growth and positive outlook, while also facing some operational challenges and regulatory uncertainties.